ArticleParkinson's disease2020
5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment.
Article in Parkinson's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Dopamine DBiomolecules · 2023Trial
- Consensus-based perspectives on integrating IPX203 into Parkinson's disease management.Journal of neurology · 2026Review
- Does genetic testing remain relevant in advanced Parkinson's disease?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: An 18-Month Longitudinal Study.Journal of clinical medicine · 2026Article
- Deep brain stimulation for Parkinson's disease in India: an expert consensus on availability, affordability, and eligibility by the Parkinson's research alliance India (PRAI).Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease.Movement disorders clinical practice · 2026Review
- Exploring Preferences and Priorities in Advanced Parkinson's Disease: A Discrete Choice Experiment.Neurology and therapy · 2026Article
- Tracking Motor Progression and Device-Aided Therapy Eligibility in Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- Clinical Outcomes and Predictors of Response to Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: A Retrospective Cohort Study over a 4-Year Period.Pharmaceutics · 2026Article
- Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson's disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study).Scientific reports · 2026Article
- Burden and disutility of sleep disturbance and early morning OFF symptoms in people with advancing Parkinson's disease: a vignette-based approach using the EQ-5D-5L.Journal of patient-reported outcomes · 2026Article
- Alignment of 5-2-1 criteria with Neurologists' clinical judgment in identifying Advanced Parkinson's Disease in Morocco: A cross-sectional inter-rater agreement study.BMC neurology · 2026Article
- Article
- Health-Related Quality of Life in Relation to the 5-2-1 Criteria in Parkinson's Disease in Sweden.Movement disorders clinical practice · 2025Article
- Knowledge of Parkinson's Disease, Perceptions of Deep Brain Stimulation, and Attitudes Toward Its Use Among Patients in Morocco: A Cross-Sectional Study.Journal of patient experience · 2025Article
- The future of Parkinson's care: a need to expand access.Frontiers in neurology · 2025Article
- New Perspectives of Deep Brain Stimulation Indications for Parkinson's Disease: A Critical Review.Brain sciences · 2024Review
- Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study.Brain sciences · 2024Article
- Towards improved access to device-aided therapies in advanced PD: the importance of cooperation of different disciplines.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objective5- (5 times oral levodopa tablet taken/day) 2- (2 hours of OFF time/day) 1- (1 hour/day of troublesome dyskinesia) criteria have been proposed by a Delphi expert consensus panel for diagnosing advanced Parkinson's disease (PD). The aim of the present study is to compare quality of life (QoL) in PD patients with "5-2-1 positive criteria" vs QoL in PD patients without "5-2-1 positive criteria" (defined as meeting ≥1 of the criteria).
methodsThis is a cross-sectional, observational, monocenter study. Three different instruments were used to assess QoL: the 39-Item Parkinson's Disease Quality of Life Questionnaire Summary Index Score (PDQ-39SI); a subjective rating of perceived QoL (PQ-10); and the EUROHIS-QOL 8-Item Index (EUROHIS-QOL8).
resultsFrom a cohort of 102 PD patients (65.4 ± 8.2 years old, 53.9% males; disease duration 4.7 ± 4.5 years), 20 (19.6%) presented positive 5-2-1 criteria: 6.9% for 5, 17.6% for 2, and 4.9% for 1. 37.5% (12/32) and 25% (5/20) of patients with motor complications and dyskinesia, respectively, presented 5-2-1 negative criteria. Both health-related (PDQ-39SI, 25.6 ± 14 vs 12.1 ± 9.2;
conclusionsQoL is worse in patients meeting ≥1 of the 5-2-1 criteria. This group of patients and their caregivers are more affected as a whole. These criteria could be useful for identifying patients in which it is necessary to optimize Parkinson's treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.